Hutchmed Enters Licensing Agreement With GSK for Cancer Drug
By Amanda Lee
Biopharmaceutical firm Hutchmed (China) said it has entered into an exclusive development and license agreement with U.K. drugmaker GSK for a cancer drug.
The deal includes a $110 million upfront payment, and potential development, regulatory and commercial milestone payments for up to a total of $1.295 billion, and royalties on net sales.
Under the agreement, Hutchmed's subsidiary, Hutchmed Limited has granted a GSK subsidiary worldwide rights, excluding Mainland China, Hong Kong, Macau, and Taiwan, to develop and commercialize the drug.
Hutchmed Limited will lead the global Phase I development program, which is expected to begin in the second half of 2026. The GSK subsidiary will manage all subsequent clinical development and commercialization activities outside of Mainland China, Hong Kong, Macau and Taiwan.
The clinical development will initially focus on colorectal, pancreatic and lung cancer indications, Hutchmed said Thursday.
Johnny Cheng, Hutchmed's acting chief executive and chief financial officer said the collaboration marked a significant step toward maximizing its potential as a treatment for patients and unlocking a new class of precision oncology medicines.
The agreement is the latest tie-up between Western pharmaceutical majors and Chinese drugmakers. This week, Swiss drugmaker Roche entered a licensing deal with China's Simcere Pharmaceutical to develop a blood cancer drug.
Write to Amanda Lee at amanda.lee@wsj.com
(END) Dow Jones Newswires
September 03, 2026 01:36 ET (05:36 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States